IRulya Therapeutics Q3 EPS $(2.31) Beats $(19.83) Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
IRulya Therapeutics (NASDAQ:IRLA) reported quarterly losses of $(2.31) per share which beat the analyst consensus estimate of $(19.83) by 88.35 percent. This is a 95.36 percent increase over losses of $(49.83) per share
IRulya Therapeutics (NASDAQ:IRLA) reported quarterly losses of $(2.31) per share which beat the analyst consensus estimate of $(19.83) by 88.35 percent. This is a 95.36 percent increase over losses of $(49.83) per share from the same period last year.